| SEC Fo | orm 4 |
|--------|-------|
|--------|-------|

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

| | Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). |
|--|--|
|--|--|

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

| OMB APPROVAL | | | | | | | | | | |
|--------------------------|-----------|--|--|--|--|--|--|--|--|--|
| OMB Number: | 3235-0287 | | | | | | | | | |
| Estimated average burden | | | | | | | | | | |

| 1 | | |
|---|--------------------------|-----|
| | hours per response: | 0.5 |
| | Estimated average burden | |

| 1. Name and Address of Reporting Person [*] BOGER KENNETH S | | | 2. Issuer Name and Ticker or Trading Symbol VERTEX PHARMACEUTICALS INC / | 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) | | | | | |
|--|---------|----------|---|--|-----------------------------------|-----------------------|--|--|--|
| | | | MA [VRTX] | | Director | 10% Owner | | | |
| (Last) | (First) | (Middle) | | X | Officer (give title below) | Other (specify below) | | | |
| (Last) (First) (Middle) C/O VERTEX PHARMACEUTICALS INCORPORATED | | () | 3. Date of Earliest Transaction (Month/Day/Year) 05/02/2011 | 1 | SVP & General Counsel | | | | |
| 130 WAVERLY ST | | | 4. If Amendment, Date of Original Filed (Month/Day/Year) | 6. Individual or Joint/Group Filing (Check Applicable Line) | | | | | |
| (Street) | | | | X | Form filed by One Re | porting Person | | | |
| CAMBRIDGE | MA | 02176 | | | Form filed by More that Person | an One Reporting | | | |
| (City) | (State) | (Zip) | | | | | | | |
| Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned | | | | | | | | | |

6. Ownership Form: Direct 5. Amount of 2A. Deemed Execution Date, 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 1. Title of Security (Instr. 3) 2. Transaction 7. Nature Securities Transaction of Indirect Date (Month/Dav/Year) Beneficially if anv Code (Instr. (D) or Indirect **Beneficial** (Month/Day/Year) 8) Owned Following (I) (Instr. 4) Ownership (Instr. 4) Reported (A) or (D) Transaction(s) Code v Amount Price (Instr. 3 and 4) Common Stock 05/02/2011 Μ 5,000 A \$24.66 121,752 D **S**⁽¹⁾ Common Stock 05/02/2011 3,614 D \$55.57(2)(3) 118,138 D Common Stock 05/02/2011 **S**⁽¹⁾ 1,386 D \$56.01⁽³⁾⁽⁴⁾ 116,752 D 401(k) Common Stock 4,660 Т Trustee 174,167⁽⁵⁾ Common Stock T of Trusts

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transa Code (8) | | of | | 6. Date Exercisable and Expiration Date (Month/Day/Year) | | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) |
|---|---|--|---|------------------------------|---|-----|-------|--|--------------------|--|--|---|--|--|--|
| | | | | Code | v | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | | | | |
| Stock Option | \$24.66 | 05/02/2011 | | М | | | 5,000 | (6) | 12/10/2011 | Common Stock | 5,000 | \$0.00 | 0 | D | |

Explanation of Responses:

1. Transaction made pursuant to Mr. Boger's company approved trading plan under Rule 10b5-1.

2. Open market sales reported on this line occurred at a weighted average price of \$55.57 (range \$55.06 to \$55.88).

3. Mr. Boger undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.

4. Open market sales reported on this line occurred at a weighted average price of \$56.01 (range \$55.90 to \$56.48).

5. Kenneth S. Boger is the trustee for trusts established for the benefit of the three adult children of Joshua S. Boger (a director of the issuer).

6. Fully vested.

Remarks:

** Signature of Reporting Person

05/03/2011

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Kenneth S. Boger

Date